Exploring the conformational dynamics and thermodynamics of EGFR S768I and G719X+S768I mutations in non-small cell lung cancer: An in silico approaches

被引:1
|
作者
Wang, Jun-Ling [2 ]
Liu, Ming-Sheng [3 ]
Fu, Yu-Dong [4 ]
Kan, Qiang-Bo [4 ]
Li, Chun-Yan [5 ]
Ma, Rong [2 ]
Fang, Zhe-Wei [2 ]
Liu, Hong-Xia [2 ]
Li, Meng-Xian [2 ]
Lv, Jia-Ling [5 ]
Sang, Peng [6 ]
Zhang, Chao [1 ]
Li, Hong-Wei [1 ]
机构
[1] Kunming Med Univ, Affiliated Qujing Hosp, Dept Oncol, Yuanlin Rd 1, Qujing 655000, Peoples R China
[2] Kunming Med Univ, Affiliated Qujing Hosp, Clin Lab, Qujing 655000, Peoples R China
[3] Kunming Med Univ, Affiliated Qujing Hosp, Dept Urol Surg, Qujing 655000, Peoples R China
[4] Kunming Med Univ, Affiliated Qujing Hosp, Dept Thorac Surg, Qujing 655000, Peoples R China
[5] Kunming Med Univ, Affiliated Qujing Hosp, Dept Oncol, Qujing 655000, Peoples R China
[6] Dali Univ, Sch Life Sci, Dali 671003, Peoples R China
来源
OPEN LIFE SCIENCES | 2023年 / 18卷 / 01期
关键词
epidermal growth factor receptor G719X and S768I mutations; non-small cell lung cancer; molecular dynamics simulation; conformation; free energy landscape; MOLECULAR-DYNAMICS;
D O I
10.1515/biol-2022-0768
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Non-small cell lung cancer (NSCLC) is often driven by mutations in the epidermal growth factor receptor (EGFR) gene. However, rare mutations such as G719X and S768I lack standard anti-EGFR targeted therapies. Understanding the structural differences between wild-type EGFR and these rare mutants is crucial for developing EGFR-targeted drugs. We performed a systematic analysis using molecular dynamics simulations, essential dynamics (ED), molecular mechanics Poisson-Boltzmann surface area, and free energy calculation methods to compare the kinetic properties, molecular motion, and free energy distribution between wild-type EGFR and the rare mutants' structures G719X-EGFR, S768I-EGFR, and G719X + S768I-EGFR. Our results showed that S768I-EGFR and G719X + S768I-EGFR have higher global and local conformational flexibility and lower thermal and global structural stability than WT-EGFR. ED analysis revealed different molecular motion patterns between S768I-EGFR, G719X + S768I-EGFR, and WT-EGFR. The A-loop and alpha C-helix, crucial structural elements related to the active state, showed a tendency toward active state development, providing a molecular mechanism explanation for NSCLC caused by EGFR S768I and EGFR G719C + S768I mutations. The present study may be helpful in the development of new EGFR-targeted drugs based on the structure of rare mutations. Our findings may aid in developing new targeted treatments for patients with EGFR S768I and EGFR G719X + S768I mutations.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Afatinib Combined with Bevacizumab in the Treatment of Patients with Non-Small Cell Lung Cancer Harboring EGFR G719X, S768I or L861Q/P Mutations
    Han, Xiang
    You, Yunhong
    Guo, Xiuhui
    Ji, Youxin
    Nie, Keke
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2024, 17 : 5503 - 5510
  • [2] Successful therapy of a critically ill non-small cell lung cancer patient with compound mutations in EGFR G719X and S768I genes using furmonertinib: A case report
    Pan, Xue
    Shi, Minhua
    HELIYON, 2024, 10 (05)
  • [3] The Effectiveness of Osimertinib in a NSCLC Patient with Complex Uncommon EGFR Mutations of G719X and S768I: A Case Report
    Ma, K.
    Wang, X.
    Cai, Y.
    Xu, Y.
    Guo, Y.
    Sun, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S935 - S935
  • [4] The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations
    Watanabe, Masahiro
    Oizumi, Satoshi
    Kiuchi, Shizuka
    Yamada, Noriyuki
    Yokouchi, Hiroshi
    Fukumoto, Shinichi
    Harada, Masao
    INTERNAL MEDICINE, 2018, 57 (07) : 993 - 996
  • [5] High Incidence of False Positives in EGFR S768I Mutation Detection Using the Idylla qPCR System in Non-Small Cell Lung Cancer Patients
    Carnero-Gregorio, Miguel
    Perera-Gordo, Enzo
    de-la-Pena-Castro, Vanesa
    Gonzalez-Martin, Jesus Maria
    Delgado-Sanchez, Julio Jose
    Rodriguez-Cerdeira, Carmen
    DIAGNOSTICS, 2025, 15 (03)
  • [6] Successful treatment of a patient with NSCLC carrying uncommon compound EGFR G719X and S768I mutations using osimertinib: A case report
    Cai, Yangyang
    Wang, Yizhuo
    Sun, Jingnan
    Wang, Xu
    Xu, Yinghui
    Sun, Chao
    Guo, Ye
    Sun, Mengyao
    Ma, Kewei
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (06)
  • [7] Good Clinical Response to Gefitinib in a Non-small Cell Lung Cancer Patient Harboring a Rare Somatic Epidermal Growth Factor Gene Point Mutation; Codon 768 AGC > ATC in Exon 20 (S768I)
    Masago, Katsuhiro
    Fujita, Shiro
    Irisa, Kaoru
    Kim, Yung Hak
    Ichikawa, Masataka
    Mio, Tadashi
    Mishima, Michiaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (11) : 1105 - 1109
  • [8] Afatinib as first-line treatment for advanced lung squamous cell carcinoma harboring uncommon EGFR G719C and S768I co-mutation: A case report and literature review
    Deng, Ruoyu
    Zhang, Wen
    Lv, Jialing
    Wang, Fang
    Chen, Yanqiong
    Jiang, Chengqi
    Guan, Yaling
    Zhang, Chao
    HELIYON, 2024, 10 (15)
  • [9] Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR Exon 20 S768I Mutant Lung Adenocarcinoma: A Case Report and Review of the Literature
    Zhu, Huijuan
    Tang, Hui
    Peng, Huizhen
    Ding, Wei
    CASE REPORTS IN ONCOLOGY, 2025, 18 (01): : 220 - 230
  • [10] Detection of the EGFR G719S Mutation in Non-small Cell Lung Cancer Using Droplet Digital PCR
    Esteva-Socias, Margalida
    Enver-Sumaya, Monica
    Gomez-Bellvert, Cristina
    Guillot, Monica
    Azkarate, Aitor
    Marse, Raquel
    Sastre, Ursula
    Blasco, Ana
    Calabuig-Farinas, Silvia
    Asensio, Victor Jose
    Terrasa, Josefa
    Obrador-Hevia, Antonia
    FRONTIERS IN MEDICINE, 2020, 7